SOTIO Announces Clinical Collaboration with MSD to Evaluate IL-15 Superagonist, SOT101, in Combination with KEYTRUDA® (pembrolizumab) in Patients…


PRAGUE, Czech Republic, Dec. 08, 2021 (GLOBE NEWSWIRE) -- SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it has entered into a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., through its subsidiaries, to evaluate the combination of SOT101, SOTIO’s IL-15 superagonist, and MSD’s KEYTRUDA® (pembrolizumab) in patients with selected advanced/refractory solid tumors in the phase 2 AURELIO-04 study.

See more here:
SOTIO Announces Clinical Collaboration with MSD to Evaluate IL-15 Superagonist, SOT101, in Combination with KEYTRUDA® (pembrolizumab) in Patients...

Related Posts